Author

D. Symmes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

B. Yuan· 1 shared E. Sho· 1 shared F. Zhou· 1 shared J. Chen· 1 shared J. Gu· 1 shared J. p. Zhang· 1 shared J. Wu· 1 shared J. Zhou· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

B. Yuan

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases

Z. Li, J. Wu, J. Zhou, B. Yuan, J. Chen, W. Wu, L. Mo, Z. Qu, F. Zhou, Y. Dong, K. Huang, Z. Liu, T. Wang, D. Symmes, J. Gu, , Y. Xu

This paper reports the preclinical efficacy of ALD-R491, a vimentin-targeting compound, in treating COVID-19 by reducing viral entry, enhancing pathogen clearance, and suppressing overreactive immune responses.

bioRxiv · Aug 26, 2021Pharmacology & Toxicology